These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24764259)

  • 1. Interferon-α is not elevated in idiopathic thrombotic thrombocytopenic purpura patients.
    Watanaboonyongcharoen P; Whinna HC; Park YA
    J Clin Apher; 2014 Dec; 29(6):336-8. PubMed ID: 24764259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic thrombocytopenic purpura in IgG4-related disease with severe deficiency of ADAMTS-13 activity and IgG4 autoantibody against ADAMTS-13.
    Saeki T; Ito T; Youkou A; Ishiguro H; Sato N; Yamazaki H; Koike T; Kourakata H; Ferrari S; Scheiflinger F; Narita I
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1209-12. PubMed ID: 21523922
    [No Abstract]   [Full Text] [Related]  

  • 3. A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13.
    Sato A; Hoshi Y; Onuma M; Sato R; Tsunematsu Y; Isonishi A; Matsumoto M; Fujimura Y; Imaizumi M
    Pediatr Hematol Oncol; 2010 Feb; 27(1):53-8. PubMed ID: 20121555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
    Thomas MR; de Groot R; Scully MA; Crawley JT
    EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura.
    Lotta LA; Valsecchi C; Pontiggia S; Mancini I; Cannavò A; Artoni A; Mikovic D; Meloni G; Peyvandi F
    J Thromb Haemost; 2014; 12(3):329-36. PubMed ID: 24354764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Yamaguchi Y; Moriki T; Igari A; Nakagawa T; Wada H; Matsumoto M; Fujimura Y; Murata M
    Thromb Res; 2011 Aug; 128(2):169-73. PubMed ID: 21496883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
    Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K
    Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic thrombocytopenic purpura with an autoantibody to ADAMTS13 complicating Sjögren's syndrome: two cases and a literature review.
    Yamashita H; Takahashi Y; Kaneko H; Kano T; Mimori A
    Mod Rheumatol; 2013 Mar; 23(2):365-73. PubMed ID: 22526830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
    Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
    Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C.
    Kitano K; Gibo Y; Kamijo A; Furuta K; Oguchi S; Joshita S; Takahashi Y; Ishida F; Matsumoto M; Uemura M; Fujimura Y
    Haematologica; 2006 Aug; 91(8 Suppl):ECR34. PubMed ID: 16923518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis C with pegylated interferon-α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura.
    Lotta LA; Degasperi E; Aghemo A; Ferrari B; Peyvandi F; Colombo M
    Transfus Med; 2013 Feb; 23(1):66-68. PubMed ID: 23106108
    [No Abstract]   [Full Text] [Related]  

  • 12. Acquired TTP: ADAMTS13 meets the immune system.
    Verbij FC; Fijnheer R; Voorberg J; Sorvillo N
    Blood Rev; 2014 Nov; 28(6):227-34. PubMed ID: 25213289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura.
    Edgar CE; Terrell DR; Vesely SK; Wren JD; Dozmorov IM; Niewold TB; Brown M; Zhou F; Frank MB; Merrill JT; Kremer Hovinga JA; Lämmle B; James JA; George JN; Farris AD
    PLoS One; 2015; 10(2):e0117614. PubMed ID: 25671313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current insight into thrombotic thrombocytopenic purpura.
    Verbeke L; Delforge M; Dierickx D
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):3-10. PubMed ID: 19851089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.
    Li D; Xiao J; Paessler M; Zheng XL
    Thromb Haemost; 2011 Nov; 106(5):947-58. PubMed ID: 21901237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Jian C; Xiao J; Gong L; Skipwith CG; Jin SY; Kwaan HC; Zheng XL
    Blood; 2012 Apr; 119(16):3836-43. PubMed ID: 22289888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
    Starke R; Machin S; Scully M; Purdy G; Mackie I
    Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura.
    Mancini I; Ferrari B; Valsecchi C; Pontiggia S; Fornili M; Biganzoli E; Peyvandi F;
    Eur J Intern Med; 2017 Apr; 39():79-83. PubMed ID: 27887777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.